Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-negative Breast Cancer × trastuzumab deruxtecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 51 Neoplasm Metastasis 21 Stomach Neoplasms 12 Carcinoma, Non-Small-Cell Lung 11 Colorectal Neoplasms 8 Neoplasms 7 Brain Neoplasms 7 Triple Negative Breast Neoplasms 5 Adenocarcinoma 5 Recurrence 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Advanced Solid Tumor 3 Salivary Gland Neoplasms 2 Pancreatic Neoplasms 2 Meningeal Carcinomatosis 2 Esophageal Neoplasms 2 Breast Cancer With Brain Metastasis 2 Uterine Neoplasms 1 Solid Cancer 1 Sarcoma 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Neoplasm, Residual 1 Melanoma 1 Lung Neoplasms 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 HER2-negative Breast Cancer 1

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡